Sanofi’s Kadmon Bolt-On Bolsters Its General Medicine Division

Deal Adds Transplant Pill Rezurock For Chronic Graft-Versus-Host Disease

 
• By Sten Stovall
Sanofi Is Paying $1.9bn cash for US Biotech • Source: Alamy

More from Deals

More from Business